About the Emerging Therapies for Childhood Leukemia Session
Childhood leukemia remains a significant focus of cancer research, with ongoing efforts to discover novel therapies to improve survival rates and minimize long-term side effects. Recent advancements in targeted therapies, such as CAR T-cell therapy and small molecule inhibitors, have shown promise in treating relapsed or refractory leukemia. These therapies work by precisely targeting cancer cells, sparing normal cells and reducing toxicity. Additionally, research into genetic mutations and biomarkers has led to the identification of new therapeutic targets, enabling more personalized treatment strategies. The goal is to enhance cure rates while minimizing the impact of treatment on the child’s development and quality of life.
Topics Covered in Emerging Therapies for Childhood Leukemia
CAR-T Cell Therapy
Bispecific T-Cell Engagers
Menin Inhibitors
Fusion-Driven Subtypes
Minimal Residual Disease
Relapsed & Refractory Disease
Related Scientific Sessions at CIOC 2027
Why Attend the Emerging Therapies for Childhood Leukemia Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Emerging Therapies for Childhood Leukemia work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Emerging Therapies for Childhood Leukemia research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Emerging Therapies for Childhood Leukemia track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Emerging Therapies for Childhood Leukemia Conference 2027 — FAQs
What is the Emerging Therapies for Childhood Leukemia track at CIOC 2027?
The Emerging Therapies for Childhood Leukemia track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Emerging Therapies for Childhood Leukemia. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Emerging Therapies for Childhood Leukemia sessions?
Cancer researchers and clinicians, educators and students with an interest in Emerging Therapies for Childhood Leukemia are all welcome — whether presenting or attending.
Can I present my research in the Emerging Therapies for Childhood Leukemia track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Emerging Therapies for Childhood Leukemia sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Emerging Therapies for Childhood Leukemia track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.